gemcitabine has been researched along with Dry Eye in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou-Alfa, GK; Bekaii-Saab, TS; Bitzer, M; Borad, MJ; Borbath, I; El-Khoueiry, A; Goyal, L; Javle, M; Kelley, RK; Li, A; Macarulla, T; Moran, S; Pande, A; Philip, PA; Roychowdhury, S; Sadeghi, S; Shepherd, SP; Soifer, HS; Tanasanvimon, S; Waldschmidt, DT; Weiss, KH; Yong, WP; Zhu, AX | 1 |
1 trial(s) available for gemcitabine and Dry Eye
| Article | Year |
|---|---|
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Central Serous Chorioretinopathy; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dry Eye Syndromes; Fatigue; Female; Gemcitabine; Humans; Hyperphosphatemia; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrimidines; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Retinal Detachment; Safety; Stomatitis; Treatment Outcome | 2021 |